Animal models of pulmonary hypertension; going beyond classical models of induction | ||||
| Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
| Article 1, Volume 5, Issue 4, October 2022, Page 151-156 PDF (554.32 K) | ||||
| Document Type: Review Articles | ||||
| DOI: 10.21608/jabps.2022.148245.1160 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Esraa Zeidan  1; Montaser Abdulhakim Khalifa2; Ashraf Taye3
| ||||
| 1Department of pharmacology and toxicology, faculty of pharmacy, Minia University, El-Minia, Egypt. | ||||
| 2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University | ||||
| 3Pharmacology and Toxicology Department, Faculty of Pharmacy, South Valley University, South Valley, Egypt. | ||||
| Abstract | ||||
| Pulmonary hypertension (PH) is a life threatening pulmonary vascular disease, characterized by elevated pulmonary arterial pressure (PAP), pulmonary vascular remodeling and right sided heart hypertrophy. Due to the emergence of right ventricular (RV) failure, PH, in spite of recent therapeutic improvements, continues to be a fatal condition. Although there are already many animal models of pulmonary hypertension accessible in research, improvement in RV function and effective remodeling reversal remain a therapeutic challenge. The right utilization of traditional and novel PH animal models is crucial for understanding the underlying pathological mechanisms to reverse severe phenomenon. This review gives a general summary of the various models for PH induction, along with each method's benefits and drawbacks. | ||||
| Keywords | ||||
| Animal models; Chronic hypoxia; Monocrotaline; Sugen; Pulmonary hypertension | ||||
|
Statistics Article View: 162 PDF Download: 333 |
||||
